Stock Watch – Hvivo

Hvivo landed its second contract this year with a pharmaceutical company based in Asia Pacific.

The AIM-listed clinical trial specialist has identified the region as a ‘key growth area’.

As part of a £6.8million deal, Hvivo will recruit healthy volunteers to test the client’s antiviral drug for respiratory syncytial virus (RSV). 

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO